Rocket Pharmaceuticals (RCKT) counsel sells small stake to cover RSU taxes

Rhea-AI Filing Summary

ROCKET PHARMACEUTICALS, INC. General Counsel Martin Wilson reported a small open-market sale of company common stock. He sold 662 shares on May 19, 2026 at an average price of $3.014 per share. Footnotes state the sale was made to cover tax withholding obligations related to vesting Restricted Stock Units that convert into common stock on a one-for-one basis. After this transaction, he continues to hold 677,977 shares of common stock, indicating the sale represents a very small portion of his overall position.

Insider Trade Summary

Net Seller: 662 shares ($1,995)

Net Sell 1 txn

Insider Wilson Martin

Role General Counsel

Sold 662 shs ($2K)

Type	Security	Shares	Price	Value
Sale	Common Stock	662	$3.014	$2K

Holdings After Transaction: Common Stock — 677,977 shares (Direct, null)

Footnotes (1)

1. Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs.

Key Figures

Shares sold: 662 shares Sale price: $3.014 per share Shares held after transaction: 677,977 shares

3 metrics

Shares sold 662 shares Open-market sale on May 19, 2026

Sale price $3.014 per share Average price for 662 shares sold

Shares held after transaction 677,977 shares Direct common stock holdings post-sale

Key Terms

Restricted Stock Units ("RSUs"), open-market sale, tax withholding obligations

3 terms

Restricted Stock Units ("RSUs") financial

"Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis."

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

tax withholding obligations financial

"The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs."

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wilson Martin

(Last) (First) (Middle)

C/O ROCKET PHARMACEUTICALS, INC.

9 CEDARBROOK DRIVE

(Street)

CRANBURY NEW JERSEY 08512

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ROCKET PHARMACEUTICALS, INC. [ RCKT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	General Counsel

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	05/19/2026		S(2)		662	D	$3.014	677,977(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis.

2. The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs.

	/s/ Martin Louis Wilson	05/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Rocket Pharmaceuticals (RCKT) report for Martin Wilson?

Rocket Pharmaceuticals reported that General Counsel Martin Wilson sold 662 shares of common stock. The sale occurred on May 19, 2026 at an average price of $3.014 per share, as disclosed in a Form 4 insider trading report.

Why did Rocket Pharmaceuticals’ General Counsel sell 662 RCKT shares?

The 662 shares were sold to pay tax withholding obligations tied to vesting Restricted Stock Units. Footnotes explain the transaction was related to RSU vesting rather than a discretionary portfolio sale, which typically carries weaker signaling value for investors.

How large is Martin Wilson’s remaining Rocket Pharmaceuticals (RCKT) position after the sale?

After selling 662 shares, Martin Wilson holds 677,977 shares of Rocket Pharmaceuticals common stock. This shows the transaction was small relative to his total holdings, with the vast majority of his equity stake remaining unchanged following the tax-related sale.

What price did Martin Wilson receive for the Rocket Pharmaceuticals shares sold?

He sold the 662 Rocket Pharmaceuticals common shares at an average price of $3.014 per share. This price reflects the execution level for the tax-related sale disclosed in the Form 4, rather than indicating any broader valuation commentary from the insider.

How many Rocket Pharmaceuticals shares did Martin Wilson sell according to the Form 4?

The Form 4 shows that Martin Wilson sold 662 shares of Rocket Pharmaceuticals common stock. The filing also notes these shares were sold specifically to satisfy tax withholding obligations associated with the vesting of previously granted Restricted Stock Units.